Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May;71(3):264-279.
doi: 10.3322/caac.21657. Epub 2021 Feb 16.

Current treatment and recent progress in gastric cancer

Smita S Joshi  1 , Brian D Badgwell  2
Affiliations
Review

Current treatment and recent progress in gastric cancer

Smita S Joshi et al. CA Cancer J Clin. 2021 May.

Abstract

Gastric cancer is not a top-10 malignancy in the United States but represents one of the most common causes of cancer death worldwide. Biological differences between tumors from Eastern and Western countries add to the complexity of identifying standard-of-care therapy based on international trials. Systemic chemotherapy, radiotherapy, surgery, immunotherapy, and targeted therapy all have proven efficacy in gastric adenocarcinoma; therefore, multidisciplinary treatment is paramount to treatment selection. Triplet chemotherapy for resectable gastric cancer is now accepted and could represent a plateau of standard cytotoxic chemotherapy for localized disease. Classification of gastric cancer based on molecular subtypes is providing an opportunity for personalized therapy. Biomarkers, in particular microsatellite instability (MSI), programmed cell death ligand 1 (PD-L1), human epidermal growth factor receptor 2 (HER2), tumor mutation burden, and Epstein-Barr virus, are increasingly driving systemic therapy approaches and allowing for the identification of populations most likely to benefit from immunotherapy and targeted therapy. Significant research opportunities remain for the less differentiated histologic subtypes of gastric adenocarcinoma and those without markers of immunotherapy activity.

Keywords: adenocarcinoma; gastric cancer; immunotherapy; molecular subtypes; stomach neoplasms.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None.

Figures

Figure 1.
Figure 1.
Separation of the greater omentum from the transverse colon and mesocolon.
Figure 2.
Figure 2.
Transection of the right gastroepiploic vessels and duodenum.
Figure 3.
Figure 3.
Ligation and transection of the left gastric vessels
Figure 4.
Figure 4.
Removal of distal portion of stomach in preparation for subtotal gastrectomy.
Figure 5.
Figure 5.
Reconstruction after subtotal gastrectomy.
Figure 6.
Figure 6.
Reconstruction after total gastrectomy.
Figure 7.
Figure 7.
Illustration of D1 or regional lymph node dissection.
Figure 8.
Figure 8.
Extra-regional, or D2, lymph node dissection.
Figure 9.
Figure 9.
Branches of celiac trunk and D2 lymph node dissection.
See this image and copyright information in PMC

References

    1. World Health Organization, International Agency for Research on Cancer, GLOBOCAN 2018: Estimated Cancer Incidence, Mortality and Prevalence Worldwide, http://globocan.iarc.fr. Accessed June 16, 2020.
    1. The American Cancer Society, Cancer Statistics Center, https://cancerstatisticscenter.cancer.org; accessed 6/16/2020.
    1. Russo AE, Strong VE. Gastric Cancer Etiology and Management in Asia and the West. Annu Rev Med. Jan 27 2019;70:353–367. doi:10.1146/annurev-med-081117-043436 - DOI - PubMed
    1. Chon HJ, Hyung WJ, Kim C, et al. Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma: Stage Adjusted Analysis From a Single High-volume Center in Asia. Annals of surgery. May 2017;265(5):946–953. doi:10.1097/SLA.0000000000001793 - DOI - PMC - PubMed
    1. Strong VE, Song KY, Park CH, et al. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Annals of surgery. Apr 2010;251(4):640–6. doi:10.1097/SLA.0b013e3181d3d29b - DOI - PubMed

Publication types

MeSH terms